The company has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov & Vysov M and has witnessed a strong uptake for the product in India for the last couple of years. It is currently available across the country.
Vildagliptin is an orally active, potent and selective DPP-4 inhibitor that improves glycemic control in patients primarily by enhancing pancreatic (and islet functions. The drug is backed by strong clinical data & is therefore a widely prescribed antidiabetic medicine for adults with type 2 diabetes mellitus. The current market size of Vildagliptin is INR 818 Cr. as per IQVIA MAT Nov' 2019 in India.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
